Close Menu

More articles about PCR

Diagenode already sells more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites, and viruses for multiple infectious diseases.

Bio-Rad will provide Roche's customers with InteliQ quality control products, Unity QC data management, as well as training and support.

The assay from San Diego-based Cue is the first molecular test authorized by the US Food and Drug Administration for home use without a doctor's prescription.

On a call with investors this week, the firm described massive revenue increases and discussed how it plans to sustain and deploy these gains.

The company also said that a previously granted EUA for its Alinity m SARS-CoV-2 assay has been expanded to include asymptomatic individuals and pooled testing.

The Temple City, California-based firm delivered approximately 3.2 million billable tests in the quarter and recorded $295.0 million in revenues.

The company said that it sold 57 T2Dx instruments in 2020, including 47 in the US, more than doubling its US installed base.

The firm said that with the addition of a target for SARS-CoV-2, its high-throughput NxTag syndromic respiratory panel includes 19 viral and two bacterial targets.

Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.

The test uses a technology called Switch-Blocker that is co-owned by the companies and enables both viral detection and strain discrimination.

The investment bank said that Lucira's COVID-19 single-use test could have widespread use with potential for adoption in the over-the-counter markets.

The RT-PCR-based test is designed to detect three SARS-CoV-2 genes in saliva samples collected in the presence of a trained observer.

The firm attributed its quarterly and annual revenue gains primarily to sales of COVID-19 testing sample collection devices.

Azova's kit is for use with Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based COVID test that previously received EUA.

Hologic said that the transaction further strengthens its molecular diagnostics business by expanding its international capabilities, among other benefits.

The firm said it is currently also developing Novodiag Resp-4, a molecular test for the rapid, on-demand detection of the viruses.

The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.

Investors responded to a report on Thursday that DiaSorin is considering the purchase of Luminex, one of its in vitro diagnostic testing competitors.

For the 12 months ended Dec. 31, 2020, Biocartis' revenues rose to €43.1 million ($52.7 million) from €37.4 million in 2019. 

The firm said its test eliminates the need for automated extraction systems in a high-volume PCR laboratory, reducing processing time, cost, and labor.

Pages

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.